BRAF V600 inhibitor (specialist)
Encorafenib
Brand names: Braftovi
Adult dose
Dose: 450mg PO OD (with binimetinib for melanoma); 300mg OD (with cetuximab for CRC)
Route: Oral
Frequency: OD
Clinical pearls
- NICE TA562/TA668 (BRAF-mutant melanoma with binimetinib); NICE TA668 (BRAF V600E CRC with cetuximab)
- ESMO melanoma / CRC guidelines
- Specialist oncology — BRAF V600 testing required
Contraindications
- Pregnancy
- Severe hepatic impairment
- Hypersensitivity
Side effects
- Pyrexia
- Fatigue
- Nausea/vomiting
- Photosensitivity
- Cutaneous SCC / new primary melanoma
- Cardiomyopathy
- QT prolongation
- Uveitis
- Haemorrhage
Interactions
- Strong CYP3A4 inhibitors/inducers
- QT-prolonging drugs
Monitoring
- LFTs
- Echo/LVEF
- ECG (QT)
- Skin surveillance
- Ophthalmic review
Reference: BNF; NICE TA562; NICE TA668; ESMO; SmPC; https://bnf.nice.org.uk/drugs/encorafenib-specialist-drug/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Breslow Thickness & Melanoma Staging · Melanoma
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis